Your session is about to expire
← Back to Search
MitoQ for Cardiovascular Disease (MOVHS Trial)
MOVHS Trial Summary
This trial will assess if a mitochondrial antioxidant (MitoQ) can reduce CVD risk among Black Americans, who are disproportionately affected by CVD. Researchers will measure blood pressure, vascular function, and biomarkers of kidney function before & after 8 weeks of MitoQ/placebo.
MOVHS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MOVHS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of kidney disease.My BMI is over 40.I have a history of diabetes.I am between 45 and 75 years old.I have a history of heart disease.I have had cancer in the past.I don't have health problems that stop me from exercising, giving blood, or taking MitoQ.My BMI is under 40.I do not have diabetes, kidney disease, lung problems, or heart and blood vessel diseases.
- Group 1: Placebo
- Group 2: MitoQ
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are adults of the requisite age being enrolled in this experiment?
"The age range for this study is 45 - 75 years old."
Is participation in this study open to the public at this time?
"According to clinicaltrials.gov, this medical research is presently recruiting patients and has been since December 6th 2022. The trial was last amended on January 31st 2023."
How many participants have been approved to take part in the experiment?
"Affirmative, according to clinicaltrials.gov the trial is actively recruiting participants as of now. It was first posted on December 6th 2022 and most recently revised on January 31st 2023. The study requires 60 individuals from a single medical site."
What are the key aims of this research project?
"This 8-week trial will measure changes in nitric oxide bioavailability as its primary outcome. Secondary outcomes include assessing levels of subjective sleepiness using the Epworth Sleepiness Scale, gauging an individual's chronotype through the Munich Chronotype Questionnaire, and quantifying insomnia severity with the Insomnia Severity Index."
What characteristics are sought in participants of this research endeavor?
"This trial is currently accepting up to 60 volunteers aged 45-75 with high blood pressure. In addition, they must display a BMI of less than 40 Kg/m2, be free from metabolic and cardiovascular diseases, have no medical conditions which impede them from exercising or donating plasma, and not suffer any allergies linked to MitoQ substances for eligibility."
Share this study with friends
Copy Link
Messenger